[go: up one dir, main page]

SI1585749T1 - Derivati diazepinoindola kot inhibitorji kinaze - Google Patents

Derivati diazepinoindola kot inhibitorji kinaze

Info

Publication number
SI1585749T1
SI1585749T1 SI200430830T SI200430830T SI1585749T1 SI 1585749 T1 SI1585749 T1 SI 1585749T1 SI 200430830 T SI200430830 T SI 200430830T SI 200430830 T SI200430830 T SI 200430830T SI 1585749 T1 SI1585749 T1 SI 1585749T1
Authority
SI
Slovenia
Prior art keywords
kinase inhibitors
diazepinoindole
derivatives
diazepinoindole derivatives
kinase
Prior art date
Application number
SI200430830T
Other languages
English (en)
Inventor
Sacha Ninkovic
Michael J Bennett
Yuanjin Eugene Rui
Fen Wang
Suzanne P Benedict
Min Teng
Yong Wang
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SI1585749T1 publication Critical patent/SI1585749T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200430830T 2003-01-09 2004-01-05 Derivati diazepinoindola kot inhibitorji kinaze SI1585749T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09
EP04700145A EP1585749B1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors
PCT/IB2004/000026 WO2004063198A1 (en) 2003-01-09 2004-01-05 Diazepinoindole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
SI1585749T1 true SI1585749T1 (sl) 2008-10-31

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430830T SI1585749T1 (sl) 2003-01-09 2004-01-05 Derivati diazepinoindola kot inhibitorji kinaze

Country Status (35)

Country Link
US (3) US6967198B2 (sl)
EP (2) EP1947102A1 (sl)
JP (1) JP3990718B2 (sl)
KR (1) KR100697746B1 (sl)
CN (1) CN1759118B (sl)
AP (1) AP2048A (sl)
AT (1) ATE404564T1 (sl)
AU (1) AU2004203977B2 (sl)
BR (1) BRPI0406701A (sl)
CA (1) CA2512683C (sl)
CR (1) CR7899A (sl)
CY (1) CY1108408T1 (sl)
DE (1) DE602004015724D1 (sl)
DK (1) DK1585749T3 (sl)
EA (1) EA009337B1 (sl)
EC (1) ECSP055911A (sl)
ES (1) ES2309484T3 (sl)
GE (1) GEP20084367B (sl)
HK (1) HK1086257A1 (sl)
HR (1) HRP20050624A2 (sl)
IL (1) IL169082A (sl)
IS (1) IS7884A (sl)
MA (1) MA27703A1 (sl)
MX (1) MXPA05007352A (sl)
NO (1) NO20053775L (sl)
NZ (1) NZ540638A (sl)
OA (1) OA13017A (sl)
PL (1) PL378372A1 (sl)
PT (1) PT1585749E (sl)
RS (1) RS20050522A (sl)
SI (1) SI1585749T1 (sl)
TN (1) TNSN05176A1 (sl)
UA (1) UA80733C2 (sl)
WO (1) WO2004063198A1 (sl)
ZA (1) ZA200504674B (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214879B2 (en) * 2002-01-22 2008-02-07 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.
SI1853721T1 (sl) * 2005-02-18 2010-06-30 Astrazeneca Ab Postopek za ugotavljanje odzivnosti na CHK inhibitorje
EP2330105A1 (en) 2005-03-29 2011-06-08 ICOS Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CA2619048A1 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
EP1942193A4 (en) 2005-08-25 2010-10-27 Ube Industries METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE (S OR R) -AMINOIC ACID OR AN OPTICALLY ACTIVE (S OR R) -α-AMINO-ACID ESTER
AU2006282767A1 (en) * 2005-08-26 2007-03-01 The Regents Of The University Of California Non-steroidal antiandrogens
CA2648371A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
CA2648369A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
US20100143332A1 (en) * 2006-11-17 2010-06-10 Schering Corporation Combination therapy for proliferative disorders
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CA2731368C (en) * 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
WO2013096687A1 (en) * 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
AU2011384859B2 (en) 2011-12-31 2016-03-17 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
EP2797921B1 (en) * 2011-12-31 2017-09-06 BeiGene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
EA037366B1 (ru) 2015-08-25 2021-03-18 Бейджин, Лтд. Способ получения ингибитора parp, кристаллические формы и их применения
MX395066B (es) 2015-09-30 2025-03-24 Vertex Pharma Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr).
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
FI3684767T3 (fi) * 2017-09-22 2024-07-22 Jubilant Epipad LLC Heterosyklisiä yhdisteitä pad:n estäjinä
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP2022523028A (ja) * 2019-01-25 2022-04-21 ヌメディー， インコーポレイテッド 特発性肺線維症を処置するための方法
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
JP7260718B2 (ja) 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
WO2022022664A1 (zh) * 2020-07-31 2022-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
JP2002526450A (ja) 1998-09-18 2002-08-20 スミスクライン・ビーチャム・コーポレイション Ｃｈｋ１キナーゼ阻害物質
AU781711B2 (en) * 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
WO2001016306A2 (en) 1999-08-27 2001-03-08 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ES2309484T3 (es) * 2003-01-09 2008-12-16 Pfizer Inc. Derivados de diazepinoindol como inhibidores de quinasa.

Also Published As

Publication number Publication date
EA009337B1 (ru) 2007-12-28
DK1585749T3 (da) 2008-09-22
WO2004063198A1 (en) 2004-07-29
IL169082A (en) 2011-02-28
OA13017A (en) 2006-11-10
CY1108408T1 (el) 2014-02-12
CA2512683A1 (en) 2004-07-29
ECSP055911A (es) 2005-11-22
PL378372A1 (pl) 2006-04-03
US20060004052A1 (en) 2006-01-05
CN1759118B (zh) 2010-12-08
HK1086257A1 (en) 2006-09-15
AP2005003353A0 (en) 2005-09-30
RS20050522A (en) 2007-12-31
NZ540638A (en) 2007-12-21
PT1585749E (pt) 2008-10-23
AU2004203977B2 (en) 2010-06-17
EP1947102A1 (en) 2008-07-23
TNSN05176A1 (fr) 2007-06-11
UA80733C2 (en) 2007-10-25
MA27703A1 (fr) 2006-01-02
KR100697746B1 (ko) 2007-03-22
JP3990718B2 (ja) 2007-10-17
US20050075499A1 (en) 2005-04-07
EP1585749A1 (en) 2005-10-19
NO20053775D0 (no) 2005-08-08
EA200500893A1 (ru) 2006-02-24
US20070135415A1 (en) 2007-06-14
ES2309484T3 (es) 2008-12-16
AU2004203977A1 (en) 2004-07-29
CR7899A (es) 2005-08-05
JP2006516274A (ja) 2006-06-29
ZA200504674B (en) 2006-07-26
NO20053775L (no) 2005-09-16
CN1759118A (zh) 2006-04-12
EP1585749B1 (en) 2008-08-13
AP2048A (en) 2009-09-24
HRP20050624A2 (en) 2006-02-28
US6967198B2 (en) 2005-11-22
US7462713B2 (en) 2008-12-09
CA2512683C (en) 2010-03-16
MXPA05007352A (es) 2006-02-17
US7132533B2 (en) 2006-11-07
IS7884A (is) 2005-06-09
ATE404564T1 (de) 2008-08-15
BRPI0406701A (pt) 2005-12-20
DE602004015724D1 (de) 2008-09-25
GEP20084367B (en) 2008-05-13
KR20050092397A (ko) 2005-09-21

Similar Documents

Publication Publication Date Title
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
EP1496910A4 (en) KINASE INHIBITORS
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
IL175568A0 (en) Azole-based kinase inhibitors
EP1558609A4 (en) KINASE INHIBITORS
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
EP1569907A4 (en) NICOTINAMIDE-BASED KINASE HEMMER
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze
AU2003906917A0 (en) Imidazopyrazine-based kinase Inhibitors
SI1684750T1 (sl) aminoariloksazolne spojine kot inhibitorji tirozin kinaze